Oncology/Hematology
Breast Cancer
More in Breast Cancer
Also in TTHealthWatch: youth and opioids, and pembrolizumab for triple-negative breast cancer
9 Hrs Ago
Broad indication doubles the number of patients eligible for adjuvant CDK4/6 inhibition
Sep 17, 2024
Absolute difference of 4.9% at 5 years, including a benefit for patients who did not achieve pCR
Sep 17, 2024
Second-line T-DXd best option in patients with and without intracranial activity, experts says
Sep 14, 2024
But benefit in modeling study accompanied by more false-positive biopsy recommendations
Aug 26, 2024
1.00
CME Credits